Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
TECH

TECH - Bio-Techne Corp Stock Price, Fair Value and News

71.76USD+0.04 (+0.06%)Market Closed
Watchlist

Market Summary

USD71.76+0.04
Market Closed
0.06%

TECH Alerts

  • Big fall in earnings (Y/Y)

TECH Stock Price

View Fullscreen

TECH RSI Chart

TECH Valuation

Market Cap

11.3B

Price/Earnings (Trailing)

50.32

Price/Sales (Trailing)

9.85

EV/EBITDA

30.85

Price/Free Cashflow

50.05

TECH Price/Sales (Trailing)

TECH Profitability

EBT Margin

21.96%

Return on Equity

11.42%

Return on Assets

8.21%

Free Cashflow Yield

2%

TECH Fundamentals

TECH Revenue

Revenue (TTM)

1.1B

Rev. Growth (Yr)

0.37%

Rev. Growth (Qtr)

-1.57%

TECH Earnings

Earnings (TTM)

224.2M

Earnings Growth (Yr)

-45.08%

Earnings Growth (Qtr)

-46.14%

Breaking Down TECH Revenue

Last 7 days

5.4%

Last 30 days

-0.8%

Last 90 days

17.3%

Trailing 12 Months

-6.1%

How does TECH drawdown profile look like?

TECH Financial Health

Current Ratio

4.37

Debt/Equity

0.23

Debt/Cashflow

0.62

TECH Investor Care

Dividend Yield

0.45%

Dividend/Share (TTM)

0.32

Buy Backs (1Y)

0.05%

Diluted EPS (TTM)

1.38

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.1B1.1B1.1B1.1B
20221.1B1.1B1.1B1.1B
2021847.8M931.0M984.6M1.0B
2020754.5M738.7M759.6M799.0M
2019702.6M714.0M734.3M744.7M
2018619.3M643.0M661.4M681.7M
2017541.2M563.0M577.0M599.4M
2016481.9M499.0M517.2M528.1M
2015434.3M452.2M456.1M465.1M
2014344.7M357.8M380.6M398.5M
2013309.8M310.6M321.2M330.2M
2012313.9M314.6M312.0M312.4M
2011278.6M290.0M299.6M306.6M
2010267.8M269.0M270.5M272.6M
20090264.0M265.2M266.5M

Tracking the Latest Insider Buys and Sells of Bio-Techne Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 01, 2024
geist william
sold (taxes)
-76,147
68.54
-1,111
president, protein sciences
Dec 19, 2023
hippel james
sold (taxes)
-2,552,230
77.42
-32,966
cfo
Dec 19, 2023
hippel james
acquired
1,478,250
31.26
47,289
cfo
Nov 01, 2023
kelderman kim
acquired
-
-
14,196
chief operating officer
Oct 26, 2023
baumgartner robert v
acquired
-
-
1,625
-
Oct 26, 2023
seth alpna
acquired
-
-
1,625
-
Oct 26, 2023
keegan joseph d
acquired
-
-
1,625
-
Oct 26, 2023
bushman julie l
acquired
-
-
1,625
-
Oct 26, 2023
vessey rupert
acquired
-
-
1,625
-
Oct 26, 2023
higgins john l
acquired
-
-
1,625
-

1–10 of 50

Which funds bought or sold TECH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 21, 2024
V-Square Quantitative Management LLC
added
18.56
80,847
315,893
0.06%
Feb 21, 2024
Raleigh Capital Management Inc.
new
-
1,157
1,157
-%
Feb 20, 2024
POLEN CAPITAL MANAGEMENT LLC
new
-
1,727,070
1,727,070
-%
Feb 20, 2024
Quarry LP
new
-
11,805
11,805
-%
Feb 20, 2024
Pacific Center for Financial Services
unchanged
-
17,271
146,604
0.05%
Feb 16, 2024
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
added
1,976
8,558,050
8,937,670
0.01%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
added
14.2
6,494
28,549
-%
Feb 16, 2024
CIM INVESTMENT MANAGEMENT INC
unchanged
-
31,679
268,903
0.09%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
added
2.85
721,569
5,070,570
0.02%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-22.46
-31,802,000
230,791,000
0.03%

1–10 of 45

Are Funds Buying or Selling TECH?

Are funds buying TECH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TECH
No. of Funds

Unveiling Bio-Techne Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
11.53%
18,228,210
SC 13G/A
Jan 24, 2024
blackrock inc.
11.5%
18,133,912
SC 13G/A
Feb 09, 2023
vanguard group inc
11.59%
18,199,432
SC 13G/A
Jan 26, 2023
blackrock inc.
10.1%
15,888,640
SC 13G/A
Jan 20, 2023
blackrock inc.
10.1%
15,888,640
SC 13G
Feb 09, 2022
vanguard group inc
11.27%
4,426,638
SC 13G/A
Jan 27, 2022
blackrock inc.
11.0%
4,328,299
SC 13G/A
Jan 25, 2022
blackrock inc.
11.0%
4,328,299
SC 13G/A
Sep 10, 2021
vanguard group inc
11.04%
4,315,543
SC 13G/A
Feb 10, 2021
vanguard group inc
9.30%
3,591,352
SC 13G/A

Recent SEC filings of Bio-Techne Corp

View All Filings
Date Filed Form Type Document
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 07, 2024
10-Q
Quarterly Report
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
3
Insider Trading
Feb 01, 2024
8-K
Current Report
Jan 24, 2024
SC 13G/A
Major Ownership Report
Jan 08, 2024
8-K
Current Report
Dec 21, 2023
4
Insider Trading

What is the Fair Value of TECH?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Bio-Techne Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Bio-Techne Corp News

Latest updates
Yahoo Finance105 minutes ago
InvestorsObserver15 Feb 202406:42 pm
InvestorPlace7 months ago

Bio-Techne Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-1.6%273277301294272270288290269258259244224204176195185183192185175
Gross Profit-4.6%177185205202183180200201184171176168151138113130121118128125113
Operating Expenses7.2%13912911012211512312011112110810710010089.0074.0082.0084.0085.0085.0081.0079.00
  S&GA Expenses9.8%11610587.0099.0093.0099.0097.0089.0010186.0087.0083.0083.0073.0057.0066.0068.0069.0069.0065.0064.00
EBITDA Margin-7.5%0.33*0.35*0.40*0.40*0.39*0.40*0.37*0.32*0.30*0.28*0.27*0.36*---------
Interest Expenses-9.5%4.005.005.000.002.003.003.002.003.003.003.003.004.004.005.004.005.005.005.00-2.5216.00
Income Taxes512.7%6.00-1.4313.0010.0016.0014.0017.009.0014.00-1.60-7.53-0.0510.006.003.0010.0031.003.006.005.004.00
Earnings Before Taxes-32.6%33.0050.0088.0080.0066.0010479.0069.0086.0067.007.0045.0056.0039.0062.0047.0015018.0023.0050.0022.00
EBT Margin-11.7%0.22*0.25*0.30*0.29*0.28*0.30*0.27*0.21*0.20*0.18*0.16*0.24*---------
Net Income-46.1%27.0051.0075.0070.0050.0090.0066.0061.0072.0069.0015.0046.0046.0033.0059.0036.0012014.0016.0045.0018.00
Net Income Margin-9.2%0.20*0.22*0.25*0.25*0.24*0.26*0.24*0.20*0.20*0.18*0.15*0.22*---------
Free Cashflow49.1%68.0046.0073.0039.0058.0047.0089.0058.0091.0042.0011164.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-0.9%2,7312,7552,6392,6002,3632,3512,2952,3002,3052,2702,2632,0852,0682,0532,0281,9991,9981,9251,8841,8731,845
  Current Assets-0.1%591591621571565552606593590544511567542542521492465392413423380
    Cash Equivalents-12.5%13014918112716516517316121219619918616616914715611010010196.0086.00
  Inventory-2.8%18118617216916015014112812211711711010710610310095.0091.0091.0094.0091.00
  Net PPE1.1%234232226224224224223218212207208199196192177165164157154145145
  Goodwill1.1%98096987387187086582282883284384395.00728732728726734730733720706
  Current Liabilities5.9%13512812914112813817616715513415213811810510710510588.0010298.0087.00
  Long Term Debt1.6%447440350370200265243247270288329203219311344407370474493510533
    LT Debt, Current-------13.0013.0013.0013.0013.0013.0013.0013.0013.0013.0013.0013.0013.0013.00-
Shareholder's Equity-1.7%1,9641,9981,9671,8901,8271,7511,7011,7131,7031,6471,5711,5481,5311,4391,3811,2911,3231,1741,1661,1461,096
  Retained Earnings-5.0%1,2611,3281,3091,2471,2001,1631,1231,1331,1461,1191,0851,0891,1051,0731,0571,0131,039931932928895
  Additional Paid-In Capital2.4%764747722715701680652636616584534514481449421382363334317298284
Shares Outstanding-0.8%157158158157157157157157157156155155---------
Minority Interest--------0.76-1.05-0.468.008.008.009.00--------
Float-----13,000---20,300---12,400---8,400---5,500
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations40.0%83.0059.0083.0051.0064.0056.0010373.0010148.0012275.0089.0066.0045.0049.0070.0041.0056.0040.0047.00
  Share Based Compensation26.4%13.0010.00-2.0810.0017.0014.008.008.0014.0012.0010.0011.0016.0013.006.008.0010.008.008.006.007.00
Cashflow From Investing84.6%-23.67-154-4.76-241-0.11-19.69-18.57-35.99-35.17-7.12-2260.00-8.60-8.14-10.4719.0033.00-15.08-30.32-4.74-13.63
Cashflow From Financing-213.8%-81.4072.00-24.22151-72.19-31.81-65.73-84.06-53.38-39.68118-55.23-90.08-34.93-44.72-17.79-97.03-24.27-19.90-27.04-41.21
  Dividend Payments-0.8%13.0013.0013.0013.0013.0013.0013.0013.0013.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.00
  Buy Backs------20.0059.0061.00---43.00---50.00---0.00-

TECH Income Statement

2023-12-31
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME    
Net sales$ 272,598$ 271,581$ 549,533$ 541,236
Cost of sales96,01188,221187,755178,280
Gross margin176,587183,360361,778362,956
Operating expenses:    
Selling, general and administrative115,66793,010220,998192,386
Research and development22,91622,45946,91446,362
Total operating expenses138,583115,469267,912238,748
Operating income38,00467,89193,866124,208
Other income (expense)(4,617)(1,462)(10,921)45,938
Earnings before income taxes33,38766,42982,945170,146
Income taxes (benefit)5,92216,4244,48630,407
Net earnings, including noncontrolling interest27,46550,00578,459139,739
Net earnings attributable to noncontrolling interest   179
Net earnings attributable to Bio-Techne27,46550,00578,459139,560
Other comprehensive income (loss):    
Foreign currency translation income (loss)18,02517,3706,423(4,087)
Foreign currency translation reclassified to earnings with Eminence deconsolidation   119
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8(3,670)(685)(4,020)4,010
Other comprehensive income (loss)14,35516,6852,40342
Other comprehensive income (loss) attributable to noncontrolling interest   (33)
Other comprehensive income (loss) attributable to Bio-Techne14,35516,6852,40375
Comprehensive income attributable to Bio-Techne$ 41,820$ 66,690$ 80,862$ 139,635
Earnings per share attributable to Bio-Techne:    
Basic (in dollars per share)$ 0.17$ 0.32$ 0.50$ 0.89
Diluted (in dollars per share)$ 0.17$ 0.31$ 0.49$ 0.86
Weighted average common shares outstanding:    
Basic (in shares)157,533157,011157,826156,887
Diluted (in shares)160,060161,750161,001161,766

TECH Balance Sheet

2023-12-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
Current assets:  
Cash and cash equivalents$ 130,132$ 180,571
Short-term available-for-sale investments5,52023,739
Accounts receivable, less allowance for doubtful accounts of $3,502 and $4,738, respectively207,451218,468
Inventories180,839171,638
Current assets held-for-sale26,647 
Other current assets40,05127,066
Total current assets590,640621,482
Property and equipment, net234,204226,200
Right of use assets100,86398,326
Goodwill980,082872,737
Intangible assets, net550,605534,645
Other assets274,359285,302
Total assets2,730,7532,638,692
Current liabilities:  
Trade accounts payable31,51425,679
Salaries, wages and related accruals32,99536,747
Accrued expenses17,15914,880
Contract liabilities28,42723,069
Income taxes payable6,64612,022
Operating lease liabilities - current12,67211,199
Contingent consideration payable 3,500
Current liabilities held-for-sale1,593 
Other current liabilities4,2251,413
Total current liabilities135,231128,509
Deferred income taxes71,57588,982
Long-term debt obligations447,000350,000
Operating lease liabilities96,02793,766
Other long-term liabilities17,36110,919
Bio-Techne's Shareholders' equity:  
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding00
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,142,004 and 157,641,914 respectively1,5711,576
Additional paid-in capital764,273721,543
Retained earnings1,261,3761,309,461
Accumulated other comprehensive loss(63,661)(66,064)
Total Bio-Techne's shareholders' equity1,963,5591,966,516
Total liabilities and shareholders' equity$ 2,730,753$ 2,638,692
TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
 CEO
 WEBSITEwww.bio-techne.com
 EMPLOYEES3050

Bio-Techne Corp Frequently Asked Questions


What is the ticker symbol for Bio-Techne Corp? What does TECH stand for in stocks?

TECH is the stock ticker symbol of Bio-Techne Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bio-Techne Corp (TECH)?

As of Thu Feb 22 2024, market cap of Bio-Techne Corp is 11.28 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TECH stock?

You can check TECH's fair value in chart for subscribers.

What is the fair value of TECH stock?

You can check TECH's fair value in chart for subscribers. The fair value of Bio-Techne Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bio-Techne Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TECH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bio-Techne Corp a good stock to buy?

The fair value guage provides a quick view whether TECH is over valued or under valued. Whether Bio-Techne Corp is cheap or expensive depends on the assumptions which impact Bio-Techne Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TECH.

What is Bio-Techne Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, TECH's PE ratio (Price to Earnings) is 50.32 and Price to Sales (PS) ratio is 9.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TECH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bio-Techne Corp's stock?

In the past 10 years, Bio-Techne Corp has provided 0.132 (multiply by 100 for percentage) rate of return.